Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | MOGAT2 | Q3SYC2 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180488 | 0.85 | HRH3 (0.53) | HRH3ESR1ESR2MOGAT2 | |
| SCHEMBL3181244 | 0.83 | HRH3 (0.51) | HRH3ESR1ESR2MOGAT2 | |
| SCHEMBL3184675 | 0.83 | HRH3 (0.72) | HRH3ESR1ESR2HRH1 | |
| SCHEMBL4437451 | 0.82 | HRH3 (0.53) | HRH3ESR1ESR2MOGAT2 | |
| SCHEMBL3171925 | 0.82 | HRH3 (0.50) | HRH3CYP2D6ESR1ESR2F10 | |
| SCHEMBL3171917 | 0.82 | HRH3 (0.48) | HRH3ITGB3ITGA2BESR1ESR2 | |
| SCHEMBL4434244 | 0.82 | HRH3 (0.53) | HRH3CYP2D6ESR1ESR2MOGAT2 | |
| SCHEMBL3176322 | 0.81 | HRH3 (0.49) | HRH3ESR1ESR2MOGAT2 | |
| SCHEMBL3176556 | 0.81 | GPR119 (0.54) | HRH3 | |
| SCHEMBL3179166 | 0.81 | HRH3 (0.49) | HRH3ESR1ESR2MOGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| EP-2114890-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008097428-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GCGR, GPR65 | HRH3 665/4885ITGB3 2381/4885ITGA2B 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.